Medtronic Achieves Highest Revenue Surge in a Decade Amid Strong Global Demand
Dublin, Thursday, 4 June 2026.
Posting a $9.8 billion fourth quarter for fiscal 2026, Medtronic achieved its highest annual revenue growth in ten years, signaling robust global demand for advanced medical technology.
Dissecting the Fourth-Quarter and Full-Year Performance
On June 2, 2026, medical device manufacturer Medtronic plc (NYSE: MDT) disclosed its financial results for the fourth quarter and fiscal year ended April 24, 2026 [1][2]. The company posted a fourth-quarter worldwide revenue of $9.807 billion, up from $8.927 billion in the same quarter of the previous year [2]. This represents a reported increase of 9.9% and an organic increase of 6.6% [1][2]. For the full fiscal year 2026, net sales reached $36.364 billion, compared to $33.537 billion in fiscal 2025, yielding a reported growth rate of 8.429% [2]. The fourth-quarter performance slightly exceeded market expectations, with revenue beating estimates by $194.45 million and non-GAAP diluted earnings per share (EPS) of $1.55 topping projections by $0.01 [3].
Strategic Portfolio Expansion and Regulatory Wins
Medtronic’s robust financial performance is underpinned by aggressive portfolio management and a steady cadence of regulatory milestones achieved throughout the quarter [1]. The company successfully completed the acquisition of CathWorks and made a strategic investment in Pulnovo Medical [1]. Furthermore, in May 2026, Medtronic announced its intentions to acquire Scientia Vascular and SPR Therapeutics to further bolster its technological edge [1]. On the regulatory front, Medtronic submitted its Hugo™ RAS system and LigaSure™ RAS vessel sealer for clearance to the U.S. Food and Drug Administration (FDA), while concurrently securing FDA clearance and the CE Mark for its Stealth AXiS™ Surgical System [1].
Shareholder Returns and Fiscal 2027 Outlook
The company’s operational rigor translated into substantial cash generation, providing a solid foundation for shareholder returns [1]. For the fiscal year ended April 24, 2026, Medtronic reported $7.330 billion in net cash from operating activities [1][2]. After dedicating $1.904 billion to property, plant, and equipment, the company realized a free cash flow of $5.426 billion [2]. Demonstrating its commitment to returning value to investors, Medtronic distributed $3.639 billion in dividends during the fiscal year [2]. On June 3, 2026, the board of directors approved an increase in the first-quarter fiscal 2027 dividend to $0.72 per share, or $2.88 annualized, marking the 49th consecutive year the company has raised its dividend payout [1].